CLICK ABOVE FOR AUDIO
COGGEN'S EXCLUSIVE OPTION
Cognitive Genetics holds an exclusive option to use the associated patents and IP to develop and commercialize DCDC2 and KIA00319 haplotype genetics research findings.
Key Patents Pending:
Two pending proprietary patents filed by Wolf, Greenfield, and Sacks, P.C., Boston, MA
US Application 13/967,291 *Issued October 2017
US Application 14/441,076 (expected 2018)
DYSLEXIA A GENETIC PROBLEM
Dyslexia – despite conventional wisdom – is actually a genetic problem that is addressable. By basing screening on genetics, we can identify children at high risk well before they struggle with reading curriculum, and even before they enter school.
Multiple independent twin and family studies show that the heritability of dyslexia is between 50% and 80% - that is to say that 50% to 80% of the variance in reading performance can be explained by genetic factors.
SCREENING FOR GLOBAL MARKET
~8 to ~15% of the global population carry the genes for the 3 main learning disabilities for which CogGen screens.
The current standard screening test for LDs is prohibitively expensive, lacks scale, and involves a long process with school teachers, specialists, pediatricians, psychiatrists, family, and the young child.
Most children suffering from LDs are not diagnosed until later in their school years if they are fortunate to be diagnosed at all.
The CogGen screener is scalable, significantly less costly, and available to be given years before a child is of reading age.